.jpg "Prof. dr Đorđe Jevtović - Specijalista infektologije")
Specijalista infektologije
Prof. dr Đorđe Jevtović, rođen 1953. godine u Beogradu, lekar-infektolog. Profesor je Medicinskog fakulteta i načelnik centra za HIV na Klinici za infektologiju i tropske bolesti u Beogradu. Dr Jevtović je objavio 208 publikacija kojima su obuhvaćene različite oblasti infektologije.
Prof. dr Đorđe Jevtović je u penziji.
Prof. dr Đorđe Jevtović, rođen 1953. godine u Beogradu, lekar-infektolog. Profesor je Medicinskog fakulteta i načelnik centra za HIV na Klinici za infektologiju i tropske bolesti u Beogradu. Dr Jevtović je objavio 208 publikacija kojima su obuhvaćene različite oblasti infektologije.
Prof. dr Đorđe Jevtović je u penziji.
Osnovne studije.
Profesor.
Načelnik centra za HIV.
Postovani, ogrebala me mačka lutalica juce po ruci. Krvarilo je. Danas sam otišla u kliniku i dali su mi tetanus vakcinu s obzirom da se ne secam kada sam zadnji put bila vakcinisana. Imam 35 god. Da li je to dovoljno? Na internetu sam pročitala da je potrebno dati i anti tetanus imunoglobin. Brinem se
dovoljna je vakcina, a imuglobulin se daje nevakcinisanim, a vi ste kao dete vakcinisani i naravno da se ne sećate
Postovani molim vas da mi odgovorite....Zanima me sve o bakteriji MRSA PVL ..kome da se obratim i da li je uopste izleciva...Hvala
multirezistentni S.aureus, najčešće je intrahospitalna infekcija, u zavisnosti od organa, ili tkiva koje je zahvaćeno, postoji lečenje.Evo u prilogu tekst iz udžbnika
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
For proven or suspected bloodstream infections, vancomycin or daptomycin
For pneumonia, vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
Table
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
For proven or suspected bloodstream infections, vancomycin or daptomycin
For pneumonia, vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
Table
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
For proven or suspected bloodstream infections, vancomycin or daptomycin
For pneumonia, vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
Poštovani, Godinu i po dana nakon završene veze sa čovekom koji je imao pozitivan test na hepatitis C, uradila sam anti hcv test i bio je negativan. Da li ima potrebe da ponavljam rezultat?
nije potrebno
Postovani doktore, nakon koliko vremena se na serioloskim testovima pokazuju virusi hepatitisa B i C, tj nakon koliko je nalaz tacan, nakon perioda prozora? Hvala Vam unaprijed
posleoko 8 nedelja, a dosta ranije je pouzdan test na virusnu DNK, odnosno RNK, PCR tehnikom
Prikazano 2816-2820 od ukupno 6060 pitanja
Na Stetoskopu lekari i stručni saradnici odgovaraju na najtraženija pitanja na Guglu. Ovo...
Dobro došli! Unesite svoje login podatke
Poštovani, imam 23 godine.
Nekoliko godina borim se sa Enterobius vermicularisom. Svaki put dobijem isti lek -Soltrik 2 sirupa, da pijem jednom uveče. Kad popijem prvu bočicu za 2 nedelje da ponovim. Međutim kroz 3 meseca gliste se uvek vraćaju. Glavni simptom je svrab oko anusa, a radila sam i perianalni bris koji potvrđuje da imam gliste.
Ne znam šta da radim, ovaj Soltrik ne pomaže, ne znam da li su gliste postale otporne, kao ni da li može da naškodi mom organizmu ako ga često pijem....
Šta mi Vi preporučujete da uradim? Hvala unapred na odgovoru. Inače sam zdrava, nemam nikakve bolesti, nisam alergična ni na šta.
Pozdrav
vi se očigledno iznova reinficirate. Neophodno je temeljno pranje veša, posteljine, na temperaturi ključana, a leče se i ostali ukućani, lekom izbora, mebendazol 1x 100mg, ili albendazol 1x400mg